Highlights Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.355 ^USD	+0.64%		+11.61%	+0.21%

Jul. 08	Xeris Biopharma Appoints John Shannon as CEO	MT
Jul. 08	Xeris Biopharma Holdings, Inc. Announces CEO Changes	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Higher in Afternoon Trading	May. 30	MT
Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise	May. 30	MT
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)	May. 30	CI
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M	May. 09	MT
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024	May. 09	CI
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product	May. 06	MT
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M	Mar. 06	MT
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Xeris Biopharma Holdings Seeks Acquisitions	Jan. 11	CI
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen	Jan. 10	MT
Xeris Biopharma Shares Climb 12% on Amgen License Agreement	Jan. 10	DJ
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment	Jan. 10	DJ
Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab	Jan. 10	CI
Xeris Biopharma Expects 2023 Revenue to be at High End of Previous Guidance; Shares Jump	Jan. 04	MT
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Year 2024	Jan. 04	CI
Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Year 2023	Jan. 04	CI
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Highlights

Filters